|
|||||
|
|
Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study |
|
| Authors: | Edward J. Gane Paul J. Pockros Stefan Zeuzem Patrick Marcellin Anna Shikhman Coen Bernaards Julian Zhou Ellen S. Yetzer Rosa Ballester Xiao Tong Isabel Nájera Anne Bertasso Janet Hammond Amy Kindrick Peter N. Morcos Patrick Smith Saray Stancic Nancy S. Shulman |
| Affiliation: | 1. Auckland Clinical Studies, Auckland, New Zealand;2. Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA;3. J. W. Goethe University Hospital, Frankfurt, Germany;4. H?pital Beaujon, Clichy, France;5. Hoffmann‐La Roche Inc, Nutley, NJ, USA;6. Genentech, South San Francisco, CA, USA;7. Roche Asia Pacific, Shanghai, China;8. Roche Products Ltd, Welwyn, United Kingdom |
| Abstract: | |
| Keywords: | chronic hepatitis C danoprevir direct‐acting antiviral interferon‐free mericitabine response‐guided sustained virological response |